AU4918697A - Method of preparing 21-alkylated pregna-1,4,16-trien-3,20-diones - Google Patents

Method of preparing 21-alkylated pregna-1,4,16-trien-3,20-diones

Info

Publication number
AU4918697A
AU4918697A AU49186/97A AU4918697A AU4918697A AU 4918697 A AU4918697 A AU 4918697A AU 49186/97 A AU49186/97 A AU 49186/97A AU 4918697 A AU4918697 A AU 4918697A AU 4918697 A AU4918697 A AU 4918697A
Authority
AU
Australia
Prior art keywords
lithium
group
solution
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU49186/97A
Inventor
Raymond E Conrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of AU4918697A publication Critical patent/AU4918697A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

METHOD OF PREPARING 21-ALKYLATED PREGNA-1 ,4,16-TRIEN-3.20-
DIONES
FIELD OF THE INVENTION
The present invention relates to methods of synthesizing intermediates which are used to prepare pharmaceutically active steroids. In particular, the present invention relates to methods of preparing 21-alkylated pregna-1 ,4,16- trien-3,20-diones.
BACKGROUND OF THE INVENTION
Pregna-1 , 4, 16-trien-3,20-diones of Formula I can be obtained using methods known in the art, for example, methods described in U.S. Patent Nos. 2,874,172; 3,033,873; 3,082,219; 3,281 ,415; 3,842,105; 4,012,510; and 4,216,159; Vitali et al., Gazz. Chem. Ital., 96:1115 (1966); Hofmeister et al., Chem. Ber., 109: 185 (1976) and Kovendi et al., Rev. Chim. (Bucharest), 27:467 (1976).
wherein X is OSiR3R4R5 or OC(=O)R6;
R3, R4, and R5 are independently C1 - C4 alkyl;
R6 is H or CT - C4 alkyl;
Y is H, F, or CI; or X and Y taken together are a covalent bond; and
Q is H or CH3. These pregna-1 ,4, 16-trien-3,20-diones are useful for making pharmaceutically valuable corticosteroids.
U.S. Patent Nos. 3,947,478 and 3,862,194 disclose the preparation of pharmaceutically valuable 21-alkylated corticosteroids starting with a 16- pregnen-20-one in which the oxygen functional group at carbon 3 is present in the form of a ketal, enol ether, or protected hydroxyl group. Functional groups are then appended at positions 16 and 17. In a subsequent step, the 21 -alkyl group is introduced by, for example, Mannich condensation or ketone alkylation reactions. The 3-keto group is unmasked at a later stage in the synthesis.
Alternative methods of preparing 21-alkylated corticosteroids are desired.
SUMMARY OF THE INVENTION
According to the present invention, pregna-1 , 4, 16-trien-3,20-diones are contacted with a base and an alkylating agent in a ketone alkylation reaction to produce corresponding 21-alkylated pregna-1 ,4, 16-trien-3,20-diones. The 21-alkylated products can be converted into pharmaceutically valuable 21- alkylated corticosteroids using techniques known in the art.
Among other factors, the present invention is based upon the finding that 21-alkylated pregna-1 ,4,16-trien-3,20-dione intermediates can be readily obtained from pregna-1 ,4, 16-trien-3,20-diones, providing convenient access to pharmaceutically valuable 21-alkylated corticosteroids.
Among other factors, the present invention is also based upon the finding that certain ketone alkylation reactions are highly selective for the 16- en-20-one grouping in the presence of a 1 ,4-dien-3-one grouping. DETAILED DESCRIPTION OF THE INVENTION
Ketone alkylation reactions are known in the art. For a discussion of the general chemical methodology employed in such reactions, see d'Angelo, Tetrahedron, 32:2979 (1976). According to the methods of the present invention, ketone alkylation reactions are used to convert pregna-1 , 4,16-trien- 3,20-diones of Formula I above into the corresponding 21-alkylated pregna- 1 ,4,16-trien-3,20-diones of Formula II below.
wherein R1 and R2 are independently H or C, - C4 alkyl (optionally unsaturated);
X is OSiR3R4R5 or OC(=O)R6;
R3, R4, and R5 are independently C-, - C4 alkyl;
R6 is H or d - C4 alkyl;
Y is H, F, or CI; or X and Y taken together are a covalent bond; and
Q is H or CH3.
Preferred compounds of Formula II are those where R1, R2, Y, and Q are H; X is OSiR3R4R5; and R3, R4, and R5 are CH3. According to the present invention, a compound of Formula I is dissolved in a suitable solvent. Suitable solvents generally include, but are not limited to, tetrahydrofuran (THF), glyme, hexamethyiphosphoramide (HMPA), 1 ,3-dimethyl-3,4,5,6-tetrahydro-2(1 H)-pyrimidinone (DMPU), diethyl ether, methyl t-butyl ether, and combinations thereof. Generally, it is desirable to cool the solution to increase the yield of the intended alkylated product. Appropriate temperatures will be determined by those skilled in the art, but will typically range from 0 to -100 °C. In most instances, it is expected that temperatures ranging from -20 to -80 °C will be sufficient for the ketone . alkylation reaction to selectively produce the intended product.
Once the solution of the compound of Formula I reaches the chosen temperature, approximately one molar equivalent of base is added. Though other ratios of base to the compound of Formula I could be employed, they are generally not desirable. If an excess of base is used, the chances for side reactions are increased. (An excess of base can form the extended enolate of the A-ring dienone; see Barton et al., J. Chem. Soc, Perkin Trans. I, p. 1075 (1977) and Barton et al., Chem. Comm., p. 1497 (1969)). On the other hand, if less than one equivalent of base is used, the yield is limited. Suitable bases include lithium diethylamide; lithium diisopropylamide; lithium dicyciohexylamide; lithium isopropylcyclohexylamide; lithium 2,2,6,6- tetramethylpiperidide; lithium hexamethyldisilazide; sodium hexamethyldisilazide; and potassium hexamethyldisilazide. The preferred base is lithium hexamethyldisilazide.
After approximately one equivalent of base has been added to the cooled solution of the compound of Formula I, at least one equivalent of an alkylating agent is added. Suitable alkylating agents are those having the formula R1R2CHZ, wherein R1 and R2 are as defined above; and Z is selected from the group consisting of Br, CI, and I. Z is preferably Br or I. As one skilled in the art will readily appreciate, it may be necessary or desirable to allow the reaction temperature to increase after adding the alkylating agent in order to improve the yield.
The following examples are presented to illustrate further various aspects of the present invention, but are not intended to limit the scope of the invention in any respect.
EXAMPLE 1 Preparation of Pregna-1 ,4,16-trien-11β-ol-3,20-dione.
a) The method of Kovendi et al., Rev. Chim. (Bucharest), 27:467 (1976) was modified. Semicarbazide hydrochloride (7.1 mL of a 5% aq. solution, 3.2 mmol) was added to a stirred, 50 °C solution of 21-deoxyprednisolone (1.82 g, 5.29 mmol) [see U.S. Patent No. 3,033,873 and Vitali et al., Gazz. Chim. Ital., 96:1115 (1966)] in acetic acid (60 mL) under Ar. The solution was heated to 75-80 °C (internal). After 2.7 h, another 4.7 mL of 5% aq. semicarbazide hydrochloride (2.1 mmol) was added. After 5.5 h at 75 °C, water (50 mL) was added and the solution was heated to 75 °C for 10 h and then to 90 °C for 1.5 h. The solution was cooled to room temperature, poured into 600 mL of water, stirred for 1 h, diluted with water to 1 L, stirred for 0.5 h and filtered on a fritted Buchner funnel. The solid was dried at 80 °C for 3-4 h to a constant weight of 1.00 g (58%, nominal) of crude product, C21 H26O3.
Proton NMR (CDCI3): d 1.22 (s, 3H, I8-H3); 1.48 (s, 3H, 19-H3), 2.27 (s, 3H, 21-H3); 1.0-2.7 (m, 12H); 4.38 (br q, 1 H, J=2.5, H-11); 6.00 (s, 1 H, H-4); 6.25 (dd, 1 H, J=10 and 2, H-2); 6.66 (q, 1 H, J=2, H-16); 7.32 (d, 1 H, J=10, H-1).
This material was converted in 75% yield to the known trimethylsilyl derivative, 11 β-(trimethylsiloxy)-pregna-1 ,4,16-trien-3,20-dione (Formula I where X = OSi(CH3)3; Y = Q = H), as described in U.S. Patent No. 4,012, 510.
SUBSTITUTE SHEET (RULE 25) b) The method of Kovendi et al., Rev. Chim. (Bucharest), 27:467 (1976) was modified. Semicarbazide hydrochloride (4.75 mL of a 5.0 % aq. solution, 2.14 mmol) was added to a stirred solution of 21-deoxyprednisolone (2.15 g, 6.25 mmol) [see U.S. Patent No. 3,033,873 and Vitali et al., Gazz. Chim. Ital., 96:1115 (1966)] in acetic acid (72 mL) under Ar. The solution was heated to 80-85 °C (bath) for 4.2 h. Water (75 mL) was added and heating (85 °C bath) was continued for 5.5 h. The solution was cooled to 23 °C over 11 h, poured into water (850 mL), cooled in ice (to 7 °C) and filtered on a fritted Buchner funnel. The solid was dried under vacuum to give 1.40 g (69%, nominal) of crude product, C21H26O3.
Proton NMR (CDCI3): d 1.22 (s, 3H, I8-H3); 1.48 (s, 3H, 19-H3), 2.27 (s, 3H, 21-H3); 1.0-2.7 (m, 12H); 4.38 (br q, 1 H, J=2.5, H-11); 6.00 (s, 1 H, H-4); 6.25 (dd, 1 H, J=10 and 2, H-2); 6.66 (q, 1 H, J=2, H-16); 7.32 (d, 1 H, J=10, H-1).
This material was converted in 83% yield to the known trimethylsilyl derivative, 11 β-(trimethylsiloxy)-pregna-1 ,4,16-trien-3,20-dione (Formula I where X = OSi(CH3)3; Y = Q = H), as described in U.S. Patent No. 4,012, 510.
EXAMPLE 2 Preparation of 21 -Methy 1-11 β-(trimethy lsiloxy)-pregna-1 ,4,16-trien-3,20- dione.
Lithium hexamethyldisilazide (estimated 0.9 M in THF, 2.1 mL, 1.9 mmol) was added over 8 min. to a stirred, cooled (-60 to -65 °C internal) solution of 11 β- (trimethylsiloxy)-pregna-1 ,4,16-trien-3,20-dione (0.73 g, 1.83 mmol) in THF (12.0 mL) and HMPA (3.0 mL) under Ar. After a further 2 min, the cloudy pale-orange mixture was quenched rapidly with iodomethane (2.5 mL, 40 mmol) whereupon the temperature rose to -57 °C and the suspension cleared. The solution was warmed over 2 min to 10 °C, quenched with sat. KH2PO4, and partitioned with EtOAc. The organic solution was dried (MgSO4), filtered and concentrated. The residue (1.9 g) was purified by chromatography (80 g silica, 25% to 50% EtOAc-hexanes) to give 0.62 g (82%) of the product, C25H36θ3Si, as an off-white solid, m.p. 178 - 182 °C (dec).
[α]23 D + 144° (c = 0.05, CHCI3).
.-1
IR(KBr) 1660, 1060, 840 cm"
Anal, calcd: C, 72.76, H, 8.79. Found: C, 72.57, H, 8.73.
MS (CI, Me3CH): 413 (m+1)(100), 323 ((m-Me3SiOH)+1)(10).
Proton NMR (CDCI3): d 0.24 (s, 9H, Me3Si); 1.05 (t, 3H, J=7.3, Me-21); 1.18 (s, 3H, I8-H3); 1.41 (s, 3H, 19-H3); 1.0 - 2.8 (m, 11 H); 2.6 (q, 2H, 21-H2); 4.37 (br q, 1 H, J=2.5, H-11); 5.99 (s, 1 H, H-4); 6.25 (dd, 1 H, J=10 and 2, H- 2); 6.64 (q, 1 H, J=2, H-16); 7.12 (d, 1H, J=10, H-1).
The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
SUBSTITUTE SHEET (RULE 25)

Claims (16)

  1. WHAT IS CLAIMED IS:
    A method of preparing a compound of the formula
    wherein R1 and R2 are independently H or C1 - C4 alkyl (optionally unsaturated);
    X is OSiR3R R5 or OC(=O)R6; R3, R4, and R5 are independently C - C4 alkyl;
    R6 is H or C1 - C4 alkyl;
    Y is H, F, or CI; or X and Y taken together are a covalent bond; and
    Q is H or CH3;
    comprising dissolving a compound of the formula
    wherein X, Y, and Q are as defined above,
    SUBSTITUTE SHEET (RULE 25) in a solvent to form a solution and contacting the solution with a base and an alkylating agent.
  2. 2. The method of Claim 1 wherein the base is selected from the group consisting of lithium diethylamide; lithium diisopropylamide; lithium dicyclohexylamide; lithium isopropylcyclohexylamide; lithium 2,2,6,6- tetramethylpiperidide; lithium hexamethyldisilazide; sodium hexamethyldisilazide; and potassium hexamethyldisilazide.
  3. 3. The method of Claim 2 wherein the base is lithium hexamethyldisilazide.
  4. 4. The method of Claim 1 wherein the alkylating agent has the formula R R2CHZ, wherein R1 and R2 are independently selected from the group consisting of hydrogen and C1 - C4 alkyl (optionally unsaturated); and Z is selected from the group consisting of Br, CI, and I.
  5. 5. The method of Claim 4 wherein R1 and R2 are H; and Z is selected from the group consisting of Br and I.
  6. 6. The method of Claim 1 wherein the solvent is selected from the group consisting of tetrahydrofuran; glyme; hexamethylphosphoramide; 1 ,3- dimethyl-3,4,5,6-tetrahydro-2(1 H)-pyrimidinone; diethyl ether; methyl t-butyl ether; and combinations thereof.
    SUBSTITUTE SHEET (RULE 25)
  7. 7. A method of preparing a compound of the formula
    wherein R1 and R2 are independently H or C - C4 alkyl (optionally unsaturated);
    X is OSiR3R4R5 or OC(=O)R6;
    R3, R4, and R5 are independently C1 - C4 alkyl;
    R6 is H or d - C4 alkyl; Y is H, F, or CI; or X and Y taken together are a covalent bond; and
    Q is H or CH3;
    comprising a) dissolving a compound of the formula
    wherein X, Y and Q are as defined above,
    in a solvent to obtain a solution; b) cooling the solution of step (a) to a temperature from about 0 to about -100 °C; c) adding approximately one equivalent of a base selected from the group consisting of lithium diethylamide; lithium diisopropylamide; lithium s dicyclohexylamide; lithium isopropylcyclohexylamide; lithium 2,2,6,6- tetramethylpiperidide; lithium hexamethyldisilazide; sodium hexamethyldisilazide; and potassium hexamethyldisilazide to the cooled solution of step (b); and d) adding at least one equivalent of an alkylating agent of the formula o R1R2CHZ, wherein R1 and R2 are as defined above; and Z is selected from the group consisting of Br, CI, and I to the solution of step (c).
  8. 8. The method of Claim 7 wherein R1, R2, Y, and Q are H; X is s OSiR3R4R5; and R3, R4, and R5 are CH3.
  9. 9. The method of Claim 7 wherein the base is lithium hexamethyldisilazide.
  10. o 10. The method of Claim 7 wherein R1 and R2 are H; and Z is selected from the group consisting of Br and I.
  11. 11. The method of Claim 7 wherein the solvent is selected from the group consisting of tetrahydrofuran; glyme; hexamethylphosphoramide; 1 ,3- 5 dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone; diethyl ether; methyl t-butyl ether; and combinations thereof.
  12. 12. The method of Claim 7 wherein the solution of step (a) is cooled to a temperature ranging from about -20 to about -80 °C in step (b).
    11
    SUBSTITUTE SHEET (RULE 25)
  13. 13. A method of preparing a compound of the formula
    wherein R1 and R2 are independently H or Ci - C4 alkyl (optionally unsaturated); and Q is H or CH3;
    comprising dissolving a compound of the formula
    wherein Q is as defined above,
    in a solvent to form a solution and contacting the solution with a base and an alkylating agent.
    12
    SUBSTITUTE SHEET (RULE 25)
  14. 14. The method of Claim 13 wherein the base is selected from the group consisting of lithium diethylamide; lithium diisopropylamide; lithium dicyclohexylamide; lithium isopropylcyclohexylamide; lithium 2,2,6,6- tetramethylpiperidide; lithium hexamethyldisilazide; sodium hexamethyldisilazide; and potassium hexamethyldisilazide.
  15. 15. The method of Claim 13 wherein the alkylating agent has the formula R1R2CHZ, wherein R1 and R2 are independently selected from the group consisting of hydrogen and C, - C4 alkyl (optionally unsaturated); and Z is selected from the group consisting of Br, CI, and I.
  16. 16. The method of Claim 13 wherein the solvent is selected from the group consisting of tetrahydrofuran; glyme; hexamethylphosphoramide; 1 ,3- dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone; diethyl ether; methyl t-butyl ether; and combinations thereof.
    13
    SUBSTITUTE SHEET (RULE 25)
AU49186/97A 1996-10-25 1997-10-22 Method of preparing 21-alkylated pregna-1,4,16-trien-3,20-diones Abandoned AU4918697A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2931296P 1996-10-25 1996-10-25
US60029312 1996-10-25
PCT/US1997/019276 WO1998018813A1 (en) 1996-10-25 1997-10-22 Method of preparing 21-alkylated pregna-1,4,16-trien-3,20-diones

Publications (1)

Publication Number Publication Date
AU4918697A true AU4918697A (en) 1998-05-22

Family

ID=21848385

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49186/97A Abandoned AU4918697A (en) 1996-10-25 1997-10-22 Method of preparing 21-alkylated pregna-1,4,16-trien-3,20-diones

Country Status (4)

Country Link
EP (1) EP0882062A1 (en)
JP (1) JP2000502370A (en)
AU (1) AU4918697A (en)
WO (1) WO1998018813A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1416427A (en) * 1972-01-12 1975-12-03 Akzo Nv Alkylated pregnanes and process for obtaining same

Also Published As

Publication number Publication date
JP2000502370A (en) 2000-02-29
WO1998018813A1 (en) 1998-05-07
EP0882062A1 (en) 1998-12-09

Similar Documents

Publication Publication Date Title
JPS6117477B2 (en)
JP2012149076A (en) PROCESS FOR PREPARATION OF 17-ESTERS OF 9α,21-DIHALO-PREGNANE-11β,17α-DIOL-20-ONES
EP1242444B1 (en) Process for preparing 17alpha-acetoxy-11beta- 4-n,n-(dimethylamino)phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes for preparing such intermediates
CA1321578C (en) 19-substituted progesterone derivatives useful as 19-hydroxylase inhibitors
US5504203A (en) Process for preparing 17,20-epoxy steroids
US4708823A (en) 17 α-chloroethynyl pregnane derivatives
EP0231671B1 (en) Gonatriene derivatives and process for preparing them
FR2493324A1 (en)
AU4918697A (en) Method of preparing 21-alkylated pregna-1,4,16-trien-3,20-diones
EP0157842B1 (en) NEW PROCESS FOR THE PREPARATION OF 17$g(a)-HYDROXY 19-NOR-PROGESTERONE DERIVATIVES
JP2021183627A (en) Method for producing 11-methylene steroid and novel intermediate
CA2238690A1 (en) Method of preparing 21-alkylated pregna-1,4,16-trien-3,20-diones
US4416821A (en) Process for preparing 16-methylene steroids
CA2427632C (en) Process for the production of 4-(17.alpha.-substituted-3-oxoestra-4,9-dien-11.beta.-yl)benzaldehyde-(1e or 1z)-oximes
US6040468A (en) Method of preparing 16α, 17α-dialkylated steroids
WO2004060906A1 (en) Process for preparing guggulsterones
ITMI941846A1 (en) PROCESS FOR THE PREPARATION OF GESTODENE
JPH08511797A (en) 17-halogeno-4-azaandrostene derivative and method for producing the same
JP2512390B2 (en) Intermediates for the production of sometimes tritiated 16-imino-17-azasteroids
US4059575A (en) Process for the preparation of 17(20)ene-21-steroid aldehydes
WO2018185783A1 (en) Novel process for preparation of 19-norsteroids
JPH037680B2 (en)
EP1036088A1 (en) Method of preparing 16 alpha,17 alpha-dialkylated steroids
JPH0119400B2 (en)
HU196433B (en) Process for producing new 20-amino-steroides

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted